• Neurocrine Biosciences average return on equity for 2024 was 15.34, a 61.99% decline from 2023.
• Neurocrine Biosciences average return on equity for 2023 was 9.47, a 83.53% increase from 2022.
• Neurocrine Biosciences average return on equity for 2022 was 5.16, a 82.26% increase from 2021.

Roe - return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.